SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-22-000561
Filing Date
2022-01-10
Accepted
2022-01-10 07:03:36
Documents
12
Period of Report
2022-01-10
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K fhtx-20220110.htm   iXBRL 8-K 43036
  Complete submission text file 0001628280-22-000561.txt   184287

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT fhtx-20220110.xsd EX-101.SCH 1905
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT fhtx-20220110_lab.xml EX-101.LAB 24844
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT fhtx-20220110_pre.xml EX-101.PRE 13246
6 EXTRACTED XBRL INSTANCE DOCUMENT fhtx-20220110_htm.xml XML 11523
Mailing Address 500 TECHNOLOGY SQUARE SUITE 700 CAMBRIDGE MA 02139
Business Address 500 TECHNOLOGY SQUARE SUITE 700 CAMBRIDGE MA 02139 617-586-3100
Foghorn Therapeutics Inc. (Filer) CIK: 0001822462 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39634 | Film No.: 22519641
SIC: 2834 Pharmaceutical Preparations